A Two-Stage Multicenter Phase II Trial of Concurrent Panitumumab Immunotherapy, Cisplatin Chemotherapy and Pelvic Radiotherapy for Primary Cancer of the Uterine Cervix Stage IB-IIIB.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Cisplatin; Panitumumab
- Indications Cervical cancer
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 17 Mar 2012 Actual end date (22 Dec 2011) added as reported by European Clinical Trials Database.
- 17 Mar 2012 Status changed from recruiting to discontinued as reported by European Clinical Trials Database.
- 22 Jul 2010 New trial record